Skip to main content

Advertisement

SpringerLink
Log in

Neurorehabilitation in multiple sclerosis—what is the evidence-base?

  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract.

Multiple sclerosis is associated with a variety of symptoms and functional deficits that result in a range of progressive impairments and handicap. The symptoms, which contribute to loss of independence and restrictions in the participation in social activities, are often responsible for a continuing decline in quality of life. The main objective of rehabilitation is, therefore, to ease the burden of symptoms by improving self-performance and independence. Compensation of functional deficits, adaptation and reconditioning, together with management of symptoms, impairment, emotional coping and self-estimation, are all important long-term objectives. Although rehabilitation has no direct influence on disease progression, recent studies indicate that this form of intervention improves personal activities and participation in social activities, thereby improving quality of life. The improvements often outlast the treatment period by several months. These findings suggest that quality of life is determined by disability and handicap more than by functional deficit and disease progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bagert B, Camplair P, Bourdette D (2002) Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management. CNS Drugs 16:445–455

    PubMed  Google Scholar 

  2. Banovac K, Wade N, Gonzalez F, Walsh B, Rhamy RK (1991) Decreased incidence of urinary tract infections in patients with spinal cord injury: effect of methenamine. J Am Paraplegia Soc 14:52–54

    CAS  PubMed  Google Scholar 

  3. Bertolene K, Coyle PK, Krupp LB (1993) Cytokine correlates of fatigue in MS. Neurology 43(Abstract):356

    Google Scholar 

  4. Branagan GW, Moran BJ (2002) Published evidence favors the use of suprapubic catheters in pelvic colorectal surgery. Dis Colon Rectum 45:1104–1108

    Article  PubMed  Google Scholar 

  5. Fantl J, Newman D, Colling J, DeLancy JOL, Keeys C, Loughery R, et al. (1996) Urinary incontinence in adults: acute and chronic management. 2nd update. Rockville,Maryland: Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. Clinical Practice Guideline, 96-0682

  6. Feinstein A, Feinstein K (2001) Depression associated with multiple sclerosis. Looking beyond diagnosis to symptom expression. J Affect Disord 66:193–198

    Article  CAS  PubMed  Google Scholar 

  7. Feinstein A, Feinstein K,Gray T, O’Connor P (1997) Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch Neurol 54:1116–1121

    CAS  PubMed  Google Scholar 

  8. Feinstein A, O’Connor P, Gray T, Feinstein K (1999) Pathological laughing and crying in multiple sclerosis: a preliminary report suggesting a role for the prefrontal cortex. Mult Scler 5:69–73

    Article  CAS  PubMed  Google Scholar 

  9. Feinstein A, O’Connor P, Gray T, Feinstein K (1999) The effects of anxiety on psychiatric morbidity in patients with multiple sclerosis. Mult Scler 5:323–326

    Article  CAS  PubMed  Google Scholar 

  10. Freeman JA, Langdon DW ,Hobart JC Thompson AJ (1997) The impact of inpatient rehabilitation on progressive multiple sclerosis. Ann Neurol 42:236–244

    CAS  PubMed  Google Scholar 

  11. Freeman JA, Langdon DW, Hobart JC, Thompson AJ (1999) Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community? Neurology 52:50–56

    CAS  PubMed  Google Scholar 

  12. Gilchrist AC, Creed FH (1994) Depression, cognitive impairment and social stress in multiple sclerosis. J Psychosom Res 38:193–201

    Article  CAS  PubMed  Google Scholar 

  13. Glenn J (2003) Restorative Nursing Bladder Training program: recommending a strategy. Rehabil Nurs 28:15–22

    PubMed  Google Scholar 

  14. Grazko MA, Polo KB, Jabbari B (1995) Botulinum toxin A for spasticity,muscle spasms, and rigidity. Neurology 45:712–717

    CAS  PubMed  Google Scholar 

  15. Haufschild T, Shaw SG, Kesselring J, Flammer J (2001) Increased endothelin-1 plasma levels in patients with multiple sclerosis. J Neuroophthalmol 21:37–38

    CAS  PubMed  Google Scholar 

  16. Humm AM, Beer S, Kool J, Magistris MR, Kesselring J, Rösler KM Quantification of Uhthoff’s phenomenon in multiple sclerosis: a magnetic simulation study. Clin Neurophysiol (in press).DOI 10.1016/j.clinph. 2004.06.010

  17. Jorger M, Beer S, Kesselring J (2001) Impact of neurorehabilitation on disability in patients with acutely and chronically disabling diseases of the nervous system measured by the Extended Barthel Index. Neurorehabil Neural Repair 15:15–22

    CAS  PubMed  Google Scholar 

  18. Kesselring J (2001) Paroxysmale Phänomene bei Multipler Sklerose. Akt Neurol 28:1–5

    Article  Google Scholar 

  19. Kesselring J (2001) Rehabilitation in MS is effective. Int MS J 8:68–71

    Google Scholar 

  20. Kesselring J, von Hippel CH (2001) Symptomatische Therapie der Multiplen Sklerose. Swiss Medical Forum 42:1051–1056

    Google Scholar 

  21. Kesselring J, Klement U (2001) Cognitive and affective disturbances in multiple sclerosis. J Neurol 248:180–183

    Article  CAS  PubMed  Google Scholar 

  22. Lee B, Bhuta T, Craig J, Simpson J (2002) Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev: CD003265

    Google Scholar 

  23. McIvor GP, Riklan M, Reznikoff M (1984) Depression in multiple sclerosis as a function of length and severity of illness, age, remissions, and perceived social support. J Clin Psychol 40:1028–1033

    CAS  PubMed  Google Scholar 

  24. Mostert S, Kesselring J (2002) Effects of a short-term exercise training program on aerobic fitness, fatigue, health perception and activity level of subjects with multiple sclerosis. Mult Scler 8:161–168

    Article  CAS  PubMed  Google Scholar 

  25. Nicolle LE (2003) Urinary tract infection traditional pharmacologic therapies. Dis Mon 49:111–128

    Article  PubMed  Google Scholar 

  26. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L,Unverzagt F (1991) Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology 41:692–696

    Google Scholar 

  27. Samkoff LM, Daras M, Tuchman AJ, Koppel BS (1997) Amelioration of refractory dysesthetic limb pain in multiple sclerosis by gabapentin. Neurology 49:304–305

    CAS  PubMed  Google Scholar 

  28. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G,Hauri D (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692–697

    Article  CAS  PubMed  Google Scholar 

  29. Sheean GL, Murray NM, Rothwell JC, Miller DH, Thompson AJ (1997) An electrophysiological study of the mechanism of fatigue in multiple sclerosis. Brain 120:299–315

    Article  PubMed  Google Scholar 

  30. Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB (1990) Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 28:512–515

    CAS  PubMed  Google Scholar 

  31. Warren JW (1997) Catheter-associated urinary tract infections. Infect Dis Clin North Am 11:609–622

    CAS  PubMed  Google Scholar 

  32. Whetten-Goldstein K, Sloan FA, Goldstein LB, Kulas ED (1998) A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 4:419–425

    Article  CAS  PubMed  Google Scholar 

  33. Whitlock FA, Siskind MM (1980) Depression as a major symptom of multiple sclerosis. J Neurol Neurosurg Psychiatry 43:861–865

    CAS  PubMed  Google Scholar 

  34. Zelenitsky SA, Zhanel GG (1996)Phenazopyridine in urinary tractinfections. Ann Pharmacother 30:866–868

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rehabilitation, Rehabilitation Centre Klinik Valens, 7317, Valens, Switzerland

    Jürg Kesselring (Head of Neurology)

Authors
  1. Jürg Kesselring
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jürg Kesselring.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kesselring, J. Neurorehabilitation in multiple sclerosis—what is the evidence-base?. J Neurol 251 (Suppl 4), iv25–iv29 (2004). https://doi.org/10.1007/s00415-004-1405-0

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-004-1405-0

Key words

Search

Navigation